静血放射疗法:对文献的叙述性综述
Pieter Verschuren1, Melissa Christiaens1, Eva Oldenburger2
1Department of Radiation Oncology, University Hospitals Leuven, Leuven, Belgium.
Annals of palliative medicine
|July 11, 2024
概括
息性放射治疗 (RT) 有效地控制了晚期癌症的出血. 虽然存在各种分成方案,但更高的生物等效剂量 (BED) 可能会提高反应率,但需要更多的研究才能制定明确的指导方针.
科学领域:
- 在瘤学瘤学.
- 辐射瘤学 辐射瘤学
- 抚慰性护理是一种缓解性护理.
背景情况:
- 流血是局部晚期癌症的常见和令人痛苦的症状.
- 放射治疗 (RT) 为癌症相关出血提供了一种非侵入性,耐受性良好,成本效益高的息治疗方法.
- 目前血液静止RT的分量剂量和时间表选择往往缺乏具体的指导方针,依赖于医生的偏好.
研究的目的:
- 审查有关息性静血放射治疗 (RT) 的现有文献.
- 为了评估响应率 (RR) 和出血持续时间与RT剂量和分数的关系.
- 确定血液静止RT的最佳治疗策略.
主要方法:
- 使用PubMed数据库进行了系统的文献搜索.
- 分析了过去20年 (至2023年12月) 发表的54篇相关文章.
- 包含和排除标准是预先确定的,以评估剂量和分成方案及其对RR的影响.
主要成果:
- 外部射线疗法 (EBRT) 和支臂疗法都有效控制出血.
- 每天或每周的低分量辐射在各种生物等效剂量 (BED) 方案中是安全和有效的.
- 较高的BED疗程可能与更持久的出血控制有关,特别是在胸部阻塞/缺血症的情况下.
结论:
- 静血RT (EBRT和支臂治疗) 是一种安全有效的息治疗,用于减少与癌症相关的出血.
- 有限的前性和统一的数据存在于静血RT分离表.
- 根据患者的病情,瘤类型和症状量身定制治疗是至关重要的;需要进一步的研究来制定明确的指导方针.
相关概念视频
02:49Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
01:05Introduction to Hemostasis
7.1K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
7.1K
01:20Extrinsic and Intrinsic Pathways of Hemostasis
7.0K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
7.0K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
672
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
672